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Epstein–Barr virus (EBV), a member of the family Herpesviridae, is widely spread in the human 
population and has the ability to establish lifelong latent infection. In immunocompetent indi-
viduals the virus reactivation is usually harmless and unnoticeable. In immunocompromised pa-
tients productive infection or type III latency may lead to EBV-associated post-transplant lym-
phoproliferative disorder (PTLD). The aim of our research was to investigate the utility of PCR-
based methods in the diagnosis and monitoring of EBV infections in bone marrow transplant 
recipients. Thirty-eight peripheral blood leukocyte samples obtained from 16 patients were ana-
lysed, in which EBV DNA was confirmed by PCR. We used semi-quantitative PCR to estimate 
the viral load and reverse-transcription PCR (RT-PCR) to differentiate between latent and pro-
ductive EBV infection. In 14 patients we confirmed productive viral infection. We observed a cor-
relation between higher number of EBV genome copies and the presence of transcripts specific 
for type III latency as well as clinical symptoms.
Keywords: Epstein-Barr virus, latency, EBV-lymphoproliferative disorder, productive infection, bone marrow transplanta-
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INTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous her-
pesvirus widely distributed in the human popula-
tion. Primary infection is asymptomatic during early 
childhood. However, in adolescents or in young 
adults, nearly half of the cases of primary infections 
manifest as mononucleosis. EBV infects mainly B 
lymphocytes and certain epithelial (lymphoepithelial) 
cells of oropharynx. Like other herpesviruses, EBV 
has the ability to establish lifelong latent infection in 
circulating B lymphocytes, so that the virus reactiva-
tion can occur, but in immunocompetent individuals 
it is usually harmless and symptomless (Rickinson & 
Kieff, 2007). Nevertheless, EBV infection may be life–
threatening in immunocompromised patients such 
as bone marrow or solid organ transplant recipients 
(Wagner et al., 2002; Tsurumi et al., 2005; Rickinson 
& Kieff, 2007). In these patients EBV reactivation 
may lead to persistent lytic infection with high viral 
load in peripheral blood lymphocytes. EBV-driven B 
cells can proliferate and progress to immunoblastic 
lymphoma which is associated with type III EBV la-
tency. In such cases the mortality rate is very high 
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and reaches 50 to 80% (Wagner et al., 2002). Early 
identification of patients at risk for developing EBV-
associated post-transplant lymphoproliferative disor-
der (PTLD) could reduce morbidity and mortality, 
thereby improving overall patient management (Re-
zonable & Paya, 2003). 
Numerous studies have confirmed the cor-
relation between high EBV viral load in peripheral 
blood and the risk of developing PTLD (Savoie et al., 
1994; Bai et al., 2000; Jebbink et al., 2003; Wagner et 
al., 2004). However, quantitative methods give no in-
formation about the stage of EBV infection. Lytic or 
productive infection is characterized by expression 
of > 60 early and capsid structural genes, whereas in 
the immortalized or continuously proliferating state, 
typical for type III latency, transcripts for the EBNAs 
and LMPs genes are present. Therefore, owing to a 
possibility of developing a severe viral disease, rap-
id, reliable and highly sensitive diagnostic methods 
for monitoring EBV infection are needed.
The aim of our research was to investigate 
the usefulness of polymerase chain reaction (PCR) 
— based methods: RT-PCR and semi-quantitative 
PCR, in the diagnosis and monitoring of bone mar-
row transplant recipients. The main purpose of the 
applied methods was the detection of EBV tran-
scripts characteristic for lytic as well as type III la-
tency, estimation of viral genome copy number and 
correlation of the results with patients’ clinical status 
after transplantation.
MATERIALS AND METHODS
Samples. We studied 38 samples of peripher-
al blood leukocytes (PBL) from 16 EBV-positive pa-
tients after allogenic haematopoietic stem cell trans-
plantation (HSCT) in different stages of engraftment. 
Prospective monitoring of our patients has shown 
that in some recipients EBV loads have fluctuated 
while in others persisted for more than 3 months. 
All analysed patients have undergone pre-emptive 
antiviral therapy with acyclovir or gancyclovir. In 
our research we also used Namalwa cells (Burkitt 
lymphoma cell line) as a positive control. Namalwa 
cells contain two copies of EBV DNA incorporated 
into the genome (Vernard et al., 2000). As a negative 
clinical control we used leukocytes obtained from 
eight EBV-negative patients (confirmed in serologi-
cal as well as in PCR tests) who had undergone allo-
HSCT.
RNA and DNA extraction. Eukocytes ob-
tained from recipients were isolated by sedimenta-
tion of 3–5 ml EDTA-treated blood samples with 6% 
dextran solution according to the method described 
by The et al. (1995). Aliquots of 1 × 106 PBL or 
Namalwa cells were used for RNA extraction by Tri-
zol Reagent (1 ml of Trizol Reagent (Invitrogen), per 
100 µl of cell suspension) and DNA extraction using 
Genomic DNA Prep Plus (A&A Biotechnology).
Viral DNA assay by nested PCR. To con-
firm the presence of EBV-1 or EBV-2, two-step PCR 
for EBNA2 was applied according to Venard et al. 
(2000) (Table 1). In EBV-positive samples the amount 
of EBV DNA was confirmed by a semi-quantitative 
PCR. Ten-fold dilutions of a DNA standard isolated 
from 1 × 106 Namalwa cells were amplified by PCR 
and separated by gel electrophoresis. DNA samples 
from patients were also diluted 10-fold, amplified, 
and the bands separated on a gel were compared 
to the standard run in parallel. The calculated EBV 
load for all samples was expressed as the number of 
EBV genome copies per 106 PBL (Fig. 1A). 
Viral mRNA assay by RT-PCR. Reverse tran-
scription of RNA samples was performed using 
oligo-dT primers (Sigma) and Mo-MLV reverse tran-
scriptase (Sigma). The efficiency of RT reaction was 
verified by PCR for β-actin (Table 1). cDNA samples 
were used to detect specific EBV transcripts by PCR. 
All PCR products were separated by electrophoresis 
and the intensity of the bands was compared and 
marked as “+”, “++”, or “+++” (Fig. 1B).
Primers were chosen to distinguish between 
EBV productive and latent infection. For that pur- 
Table 1. Targets for primers used in PCR and RT-PCR
Stage of infection: Gene/transcript Product According to:
House-keeping gene – Beta-actin 307 bp Guzik et al., 1999 
EBV
Confirmation of infection EBNA2/EBV1 or 2 497 bp or 150 bp Vernard et al., 2000 
Productive infection
BZLF1 608 bp Mundle et al., 2001 
BALF2 238 bp118 bp Prang et al., 1997 
Type III latency
EBNA2 596 bp497 bp Venard et al., 2000 
LMP1 351 bp198 bp Qu et al., 2000 
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pose, transcripts of productive infection: BZLF1 
(immediate-early) and BALF2 (early) and type III 
latency transcripts for viral oncogenes — EBNA2 
and LMP1 — were detected (Table 1). We per-
formed two-step PCRs (nested PCRs) for detec-
tion of BALF2, EBNA2 and LMP1 transcripts to 
increase the sensitivity of the method. PCR for 
BZLF1 transcript was one-step.
RESULTS
The results obtained for blood samples of 
EBV-positive patients are presented in Table 2. 
The presence of EBV-1 was confirmed in all 38 
samples of PBL. Basing on the serological tests be-
fore transplantation in the donor–recipients pairs, 
primary EBV-infection could be recognized in two 
patients (no. 12 and 13), while in the others the 
presence of EBV-1 was a result of reactivation or 
possibly reinfection. Samples were collected at 
different stages of engraftment (from one to 29 
months after HSCT).
Isolated RNA was analysed by RT-PCR to 
differentiate between productive and latent EBV 
infection and mostly to detect transcripts specific 
for type III latency, connected with a higher risk 
for developing PTLD. In all studied samples the 
transcript for the house-keeping gene β-actin was 
detected, which confirmed the efficiency of RNA 
extraction and RT reaction. Moreover, all specific 
transcripts were present in the Namalwa cell line 
used as a positive control. In no material obtained 
from uninfected patients, serving as a negative 
clinical control (results not shown in Table 2), did 
we detect any EBV transcripts.
Productive infection was detected in 14 of 16 
analysed patients (patients no. 3–16). Almost in all 
of the samples (83%) a transcript for the BALF2 gene 
(essential in the lytic phase of the viral replication) 
was detected, while a transcript for the immediate-
early gene BZLF1 was detected only in 19% of ma-
terials obtained from four patients (patients no. 6, 9, 
12 and 13). It is possible that the difference in the 
number of positive samples for productive infection 
of EBV is a consequence of the different sensitivity 
of one-step and two-step PCR. It is also possible that 
the detection of further stages of EBV lytic infection 
(i.e. for late genes) may be much more useful in the 
diagnostics of bone marrow transplant recipients.
Transcripts for viral oncogenes EBNA2 and 
LMP1, specific for type III latency of EBV, were de-
tected in 5 of 16 patients (patients no. 4, 9, 12, 13 
and 15) although expression of the BZLF1 and/or 
BALF2 genes, characteristic for lytic infection, was 
also confirmed. In patients no. 1 and 2 only LMP1 
transcript was present, which confirmed the latent 
stage of EBV infection, but not type III latency. 
The aim of the semi-quantitative PCR analy-
sis was to estimate the number of EBV viral genome 
copies in the DNA samples studied. A number of 
EBV genome copies (between 2 000 and 20 000 per 
1 × 106 leukocytes) was demonstrated for 8 out of 16 
patients, and in six of them (patients no. 3, 4, 12, 
13, 14 and 15) the higher viral load correlated with 
symptoms such as graft versus host disease (GvHD), 
increased levels of transaminases, thrombocytopenia, 
and fever. For patient no. 15, between 7 to 9 months 
after transplantation, we observed an increase of the 
EBV copy number from 200 to 20 000 per 1 × 106 PBL 
without clinical symptoms (data not included in Ta-
ble 2). Furthermore, samples of patient no. 14 col-
lected after 1.5 and 2 months following HSCT were 
only positive for the BALF2 transcript specific for 
productive infection and the estimated EBV genome 
copy number was low – 200 per 1 × 106 PBL. Because 
in these sample the presence of HHV7 was also 
detected, the high level of transaminases may be a 
result of a mixed infection. In the sample collected 
from the same patient 3 months after transplanta-
tion, we additionally confirmed the LMP1 transcript 
that accompanied an increase of the EBV genome 
number to 2 000 per 1 × 106 PBL and the appearance 
of thrombocytopenia. 
Figure 1. Examples of gel electrophoresis pattern of PCR 
products.
A. PCR for EBNA2/EBV1. Serial dilution of DNA obtained 
from 106 Namalwa cells (upper panel) and DNA obtained 
from two selected patients’ samples (bands no. 1–3 and 
4–6). PC, positive control, DNA isolated from Namalwa 
cell line (band no. 7). B. RT-PCR for LMP1 showing differ-
ent intensity of gel bands; bands no. 1 and 12, molecular 
marker, no. 2–10 selected samples, no. 11, positive control 
from Namalwa cells.
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A low number of EBV genome copies, 200 
per 1 × 106 PBL, was usually found in samples of 
“healthy” recipients. The increasing viral load ob-
served in patient no. 4, as well as the decreasing 
EBV load in patient no. 3 correlated well with their 
clinical status. 
In our study patients were examined for EBV 
transcripts between 1 and 29 months after HSCT. 
For most of the patients, samples were collected 
within a year, on average 4.7 ± 2.8 months after 
HSCT, and also later, except for patients no. 5 and 6, 
whose samples were examined only late after trans-
plantation. The highest risk of developing PTLD has 
been reported for the first year after transplanta-
tion, when the recipients’ effective cytoxic immune 
response against EBV-infected B lymphocytes was 
recovering (Bhatia et al., 1996). In our patients we 
did not observe such complication, neither have we 
found typical type III latency, without a productive 
gene expression. However, in samples with reason-
ably high EBV copy number (> 200 per 106 PBL) the 
EBNA2 and/or LMP1 transcripts, characteristic for 
type III latency, were detected significantly more of-
ten, at 67% vs. 30% in low-load samples (Fisher ex-
act test, P = 0.03).
DISCUSSION
Developing reliable and highly sensitive meth-
ods for Epstein–Barr virus detection is crucial for 
the growing number of immunosuppressed patients. 
In immunocompetent seropositive hosts, EBV is 
controlled by cell-mediated immunity and the pres-
ence of viral genome is usually undetectable in PBL 
(Hopwood et al., 2002). Immunosuppressive therapy 
may increase the number of peripheral EBV-driven 
B cells. In our allo-HSCT patients we observed tran-
sient EBV appearance in blood cells. From our stud-
ied group three patients (no. 9, 12 and 13) were per-
sistent EBV carriers for more than 3 months. In one 
carrier, low copy number (200 copies/106 PBL) was 
detected, whereas in two others a high viral load was 
observed as a result of primary infection. Increasing 
virus load was associated with clinical symptoms. 
Because for some patients we had confirmed other 
herpesviruses in the same samples (Zawilinska et al., 
2006), it cannot be concluded definitively that these 
symptoms were caused by EBV only.
In most reports EBV DNA levels in patients 
with PTDL are significantly higher than in healthy 
recipients (Hopwood et al., 2002). In our patients the 
highest level of virus loads was 20 000 copies per 106 
PBL although in none of them PTDL was observed. 
So we additionally analysed the expression of spe-
cific EBV transcripts which reflected EBV productive 
infection or latency. Progressive features, ranging 
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from reactive hyperplasia to monomorphic B cell 
lymphoma (Nalesnik, 1998; Barrett, 2000), difficulties 
in PTLD diagnosis and usually a fatal outcome of 
the disorder (Wagner et al., 2002) are reasons for the 
application of new diagnostic methods for detection 
of EBV infection and PTLD. 
In our investigation we were able to detect 
productive infection in the majority of studied pa-
tients (even asymptomatic ones) in contrast to Ber-
gallo and co-workers who confirmed such infection 
in only one of 30 asymptomatic renal recipients (Ber-
gallo et al., 2007). The results of our study indicate 
also that there is a correlation between the higher 
number of EBV genome copies and the presence 
of transcripts specific for type III latent infection. It 
may be proposed that the appearance of EBV-infect-
ed B lymphocytes with type III EBV latency can in-
duce excessive viral replication, or that an increased 
number of lytic EBV-infected B cells results in the 
expression of type III latent genes in other infected 
lymphocytes. The quantitative methods more often 
applied in the diagnosis of EBV infection, such as 
real-time PCR (Savoie et al., 1994; Bai et al., 2000; 
Jebbink et al., 2003; Wagner et al., 2004), can be use-
ful in predicting the risk of developing PTLD, even 
though the risk is directly related to EBV latent in-
fection in contrast to other herpesviruses, in which 
case the productive phase of the life cycle causes 
virus-associated diseases in transplant recipients 
(Rayes et al., 2005). 
To conclude, these preliminary results indi-
cate that PCR-based assays seem to be useful in the 
monitoring of EBV infection in bone marrow trans-
plant recipients. Semi-quantitative PCR is regarded 
as a valuable tool for estimating EBV genome copy 
number and also allows evaluation of the risk for 
patients, since a high amount of EBV DNA is one 
of the major risk factors for developing PTLD. How-
ever, our results and another study show that an 
increased viral load in transplant recipients is not 
always predictive of PTDL (Tysarowski et al., 2007). 
Using the RT-PCR method in our study addition-
ally allowed us to differentiate between productive 
and latent infection. Therefore, application of several 
methods, rather than only one, for monitoring trans-
plant recipients seems to be more reliable and gives 
much more information about EBV infection. Early 
identification of patients at risk for developing PTLD 
could reduce PTLD-related morbidity and mortality 
by appropriate patient management.
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